Eyecheck Announces FDA IND Clearance of STRI Formula, the First-Ever

Food-Based, Combination Product in the STRI Phase 2 Clinical Trial for

COVID-19 Symptoms

Eyecheck intends to initiate the Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial to
evaluate STRI Formula in non-hospitalized adults with COVID-19. This trial is expected to begin in
November 2021.

Chicago, IL November 04, 2021 --(PR.com)-- Eyecheck, Inc. today announced the clearance of the
Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to
evaluate STRI Formula in non-hospitalized adults with COVID-19 in the Study to Reinforce Immunity
(STRI) Phase 2 Clinical Trial (clinicaltrials.gov NCT05046561). STRI Formula is a combination of nine
food-based ingredients that have been shown to display immunosupportive effects in controlled
laboratory experiments. The IND is active, and Eyecheck intends to initiate the trial in November 2021.

“COVID-19 continues to be a significant cause of morbidity and mortality in the United States and
throughout the world. We hope that STRI Formula will help individuals in the STRI Phase 2 Clinical
Trial experience relief from COVID-19 symptoms more quickly,” said Rama D. Jager, MD, Founder and
Chief Medical Officer.

“At Eyecheck, our mission is to utilize evidenced-based nutrition for everyday health. STRI Formula has
been specifically formulated as a food-based regimen to help individuals with COVID-19 in the STRI
Phase 2 Clinical Trial. We are excited to launch the trial and investigate the potential of STRI Formula
for COVID-19 symptom management,” stated J. Anthony Moses, CEO.

About the STRI Phase 2 Clinical Trial

The STRI Phase 2 Clinical Trial is an IRB-approved, randomized, double-blind, placebo-controlled

clinical trial sponsored by Eyecheck, Inc. and conducted by Beat COVID LLC. The primary endpoint in
the STRI Phase 2 Clinical Trial is the length of time to initial meaningful clinical improvement in
COVID-19 symptoms. Secondary endpoints of the STRI Phase 2 Clinical Trial include an assessment of
rates of hospitalization, fever, and hypoxia. Eyecheck hopes that STRI Formula will help people with
COVID-19 get better faster. For further information regarding the STRI Phase 2 Clinical Trial, please
visit https://beatcovidtrial.com.

About Eyecheck

Eyecheck is a company dedicated to offering physician-formulated, clinically-validated, and

independently-certified premium products to support everyday health. Eyecheck’s products are
meticulously formulated using evidence-based research from peer-reviewed reports of clinical studies to
help support, maintain, and improve people’s health. For further information on Eyecheck, please visit
https://eyecheck.com.

Page 1 of 3
PR.com Press Release Distribution Terms
About Beat COVID

Beat COVID is a group of leading physician-scientists, clinical researchers and doctors working together
to try to slow the spread of COVID-19. Our mission is simple: We are trying to flatten the curve. For
further information regarding Beat COVID, please visit https://beatcovidtrial.com.

About COVID-19

Starting in December 2019, a novel coronavirus designated SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus 2), spread via close contact, respiratory droplets, and aerosols, has caused an
international pandemic of respiratory illness termed COVID-19. COVID-19 ranges from a mild,
self-limiting respiratory disease to severe progressive pneumonia, multiorgan failure, and death.

Contacts
Beat COVID LLC (https://beatcovidtrial.com)

Principal Investigator
Rama D. Jager, MD, MBA, FACS
rjager@beatcovidtrial.com

Clinical Trial Manager

Ambika Sharma, BS
asharma@beatcovidtrial.com

Clinical Trial Coordinators

Taron D. Asatryan, BSLAS
tasatryan@beatcovidtrial.com

Melissa Ruelas, BHS, CCMA

mruelas@beatcovidtrial.com

Page 2 of 3
PR.com Press Release Distribution Terms
Contact Information:
Eyecheck, Inc.
Rama Jager
(708) 620-4608
Contact via Email
beatcovidtrial.com

Online Version of Press Release:

https://www.pr.com/press-release/848302

Page 3 of 3
PR.com Press Release Distribution Terms